Clinical Trial Update: Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating intestinal low-dose radiotherapy plus immunochemotherapy, including tislelizumab, to convert borderline resectable or unrese…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Chuangzhen Chen | Conditions: Borderline Resectable Carcinoma, Unresectable Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING